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CoronavirusViral ion channels are short membrane proteins with 50–120 amino acids and play an important role either
in regulating virus replication, such as virus entry, assembly and release or modulating the electrochemical
balance in the subcellular compartments of host cells. This review summarizes the recent advances in viral
encoded ion channel proteins (or viroporins), including PBCV-1 KcV, inﬂuenza M2, HIV-1 Vpu, HCV p7,
picornavirus 2B, and coronavirus E and 3a. We focus on their function and mechanisms, and also discuss viral
ion channel protein serving as a potential drug target.Chinese Academy of Sciences,
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Since M2 protein of inﬂuenza virus A was reported to have ion
channel activity in 1992 [1], several ion channel proteins encoded by
viruses have been discovered. This new family of virus proteins that
enhance membrane permeability was named viroporins, and includes
small proteins that contain at least one hydrophobic transmembrane
(TM) domain [2]. Typically, viroporins are comprised of 50–120 aminoacids (Table 1), which tend to form homo-oligomers, most of them
frequently forming tetramers. Oligomerization of these subunits
produces a hydrophilic pore which facilitates ion transport across host
cell membranes. The functions of these viral channel proteins may be
involved in many stages of the virus infection cycle.
2. Function of viral ion channels
2.1. PBCV-1 Kcv
Chlorella virus PBCV-1 encodes a 94 aa protein, Kcv, which has two
transmembrane domains separated by 44 amino acids that contain
Table 1
List of several viral encoded ion channel proteins.
Virus family Viral channel AA
residues
TM References
Picornaviridae Poliovirus 3A 87 1 [3–5]
Poliovirus 2B 97 2 [4–6]
Coxsackievirus B3 2B 99 2 [7,8]
EV71 2B 99 2
(predicted)
Togaviridae SFV 6K 60 2 [9]
Sindbis virus 6K 55 1
(predicted)
[10]
Ross River virus 6K 62 1
(predicted)
[11]
Retoviridae HIV-1 Vpu 81 1 [12–14]
Paramyxoviridae HRSV SH 64 1 [15]
Orthomyxoviridae Inﬂuenza A virus M2 97 1 [1,16,17]
Inﬂuenza B virus NB 100 1 [18–20]
Inﬂuenza B virus
BM2
115 1 [21,22]
Inﬂuenza C virus
CM2
115 1 [23–26]
Reoviridae ARV p10 98 1
(predicted)
[27]
Flaviviridae HCV p7 63 2 [28,29]
Phycodnaviridae PBCV-1 Kcv 94 2 [30–32]
ATCV-1 Kcv 82 2
(predicted)
[33]
Rhabdoviridae BEFV alpha-1 protein 88 1
(predicted)
[34]
Coronaviridae SARS-CoV E 76 1 [35,36]
MHV E 83 1
(predicted)
[37,38]
SARS-CoV 3A 274 3 [39,40]
EV71, Enterovirus 71; SFV, Semliki forest virus; HIV-1, human immunodeﬁciency virus
type 1; HRSV, human respiratory syncytial virus; ARV, avian reovirus; HCV, Hepatitis C
virus; PBCV-1, Paramecium bursaria chlorella virus; ATCV-1, Acanthocystis turfacea
chlorella virus; BEFV, bovine ephemeral fever virus; MHV,murine hepatitis virus; SARS-
CoV, Severe acute respiratory syndrome-associated coronavirus.
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Xenopus oocytes [30] or mammalian HEK293 [32] and CHO cells [41],
Kcv shows a potassium-selective conductance, which is sensitive to
the typical K+ channel blockers Ba2+. The PBCV-1 Kcv channel has an
overall K+ channel architecture, which is similar to the bacterial
channels KcsA and KirBac aswell as to eukaryotic Kir channels [42,43].
Kcv alignment with KcsA (a pH-gated bacterial K+ channel) indicates
42% aa similarity and 19% aa identity [41].
Six Kcv-like proteins forming functional K+-selective channels were
identiﬁed from 40 additional chlorella viruses [44]. Recently a K+
channel protein (82 amino acids, named ATCV-1 Kcv) was found in
another chlorella virus, acanthocystis turfacea chlorella virus, which
was demonstrated in Xenopus oocytes and K+ uptake deﬁcient
Saccharomyces cerevisiae [33]. It seems that chlorella viruses are a rich
source of ion channel genes [45].
Infection of chlorella NC64A cells by PBCV-1 produces a rapid
depolarization of the host cell. Kcv is considered responsible for the
depolarization and is related to modulation of the efﬂux of potassium
ions [46]. The host membrane depolarization may have two functions
during PBCV-1 infection. Firstly, the virus-triggered K+ efﬂux occurs
at the same time as the host cell wall is broken and viral DNA is
ejected. It was postulated that loss of K+ is associated with an ejection
of DNA from the virus particles into the host. Secondly, when the
unicellular green alga is inoculated with two viruses, usually only
one virus replicates in a single cell [47]. Timo Greiner et al.
demonstrated that virus-induced host membrane depolarization,
presumably triggered by a virus-encoded K+ channel (Kcv) located
in the virus internal membrane and by the rapid release of K+ from
the cell, is at least partially responsible for this mutual exclusion
phenomenon [48].2.2. Inﬂuenza virus M2
The inﬂuenza A virus M2 protein, the most well-studied viral
proton channel, is a 97 residue single-pass membrane protein [49]
which forms homo-tetramers [50]. Pinto et al. ﬁrst demonstrated the
ion channel activity of M2 in Xenopus laevis oocytes [1]. Its channel
activity was further studied in mammalian cells [51,52] and lipid
bilayers [17]. Schroeder et al. indicated its proton transfer activity by
functional reconstitution of M2 in lipid vesicles [53], and its selective
proton permeability also detected in mouse erythroleukaemia (MEL)
cells expressing M2 protein [52]. The BM2 of inﬂuenza B virus also
shows proton channel activity [21]. However, the CM2 of inﬂuenza C
virus forms a voltage-activated ion channel permeable to chloride ion
in Xenopus laevis oocytes [26].
The transmembrane domain of inﬂuenza A virus A/M2 and inﬂuenza
B virus BM2 both contain themotif HXXXW. The high proton selectivity
of A/M2 is conferred by histidine residue 37 [54], and the channel gate is
conferred by tryptophan 41 [55] . At low pH, the His37 H+ selectivity
ﬁlter becomes protonated and the indole ring of Trp41 rotates to permit
protons to pass. The function of M2 channel activity is to promote virus
uncoating in endosomes [56] and to affect glycoprotein processing and
trafﬁcking [57,58].
The cytoplasmic domain of inﬂuenza A virus M2 protein consists of
54 amino acid residues from 44 to 97aa. Distinct domains of this part of
M2 mediate its binding to M1 protein and facilitate virus production
[59]. The cytoplasmic part ofA/M2also found to interactwith caveolin-1
[60], is a host a cholesterol-binding protein enriched in lipid raft [61].
However, the effect of this interaction needs further investigation.
2.3. HIV-1 Vpu
Vpu is a 16 kDa protein expressed by HIV-1 gene vpu, which is
absent fromHIV-2 and other simian immunodeﬁciency viruses except
for the simian immunodeﬁciency virus of the chimpanzee (SIVcpz)
[62,63]. The Vpu was encoded by the Rev-dependent bicistronic
mRNA and has three α-helices: one in the transmembrane domain at
the N-terminal and the other two in the cytoplasmic domain [64,65].
The two serines at positions 52 and 56 within the cytoplasmic domain
were found to be phosphorylated by casein kinase (CK-2), a process
important to the CD4 degradation function of Vpu [66].
In some cell lines, Vpu is essential for the release of virus particles
[62,67,68]. The absence of Vpu in a viral genome can lead to the
retention of virus particles in the cell plasma membrane [68]. In early
studies, it was unclear how the deﬁciency of Vpu might affect virus
release. Nevertheless, some functions of Vpu were determined. Firstly,
Vpu can lead to the degradation of CD4 [69], which seems to be
irrelevant to the activity of Vpu in enhancement of virus release [65,70].
Next, the transmembranedomain at theN-terminal of Vpuwas found to
have ion channel activity in vitro and to be involved in the regulation of
virus release [14]. Themutant Vpuwith no CD4 degradation activity can
also facilitate virus release. Moreover, additional expression of Vpu
protein of HIV-1 enhances the release of several other viruses, including
Sindbis virus, murine leukemia virus (MLV), HIV-2 and visna virus
[14,71]. However, with these limited data, we cannot understand the
detailed mechanism that how Vpu facilitates virus release.
Subsequently, investigators' attention was drawn to themechanism
by which Vpu can induce CD4 degradation. Brieﬂy, h-βTrCP, a human
WD protein, can interact with Vpu as it connects to CD4; this βTrCP–
Vpu-CD4 complex then interacts with sKp1p, a targeting protein for
ubiquitin-mediated proteolysis, and ﬁnally leads to the degradation of
CD4 by the ER-associated ubiquitin pathway [72,73]. At nearly the same
time, Vpu was found to have high homogeneity with the ﬁrst
transmembrane domain TASK-1, a mammalian endogenous potassium
channel [74]. It was reported that Vpu could interact with TASK-1 and
form dysfunctional hetero-multimers which may reduce the activity of
TASK-1 and lead to a degradation of this potassium channel. On the
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regarded as a functional equivalent for Vpu in virus release. However
this work has never been conﬁrmed in any later work.
The most recent studies were based on some interesting phenom-
enon. It was observed that the dependence of Vpu in HIV release is
present in somecell lines (HeLa etc.) but absent in others (COSetc.) [75].
In additions, this dependence could be induced by interferon-α in 293T
cells or enhanced in Jukat cells [76]. A study on fusion of between HeLa
and COS-7 cells suggested the existence of an inhibitor to virus release
which could be antagonized byVpuprotein inHeLa cells but not in COS-
7 cells [75]. Finally this inhibitor, CD317/BST2, was revealed by using
RNA microarray and was named ‘tetherin’ [77]. Later studies demon-
strated that the inhibition by CD317/BST2 of virus release is a common
mechanism through which host cells protect themselves. A similar
phenomenon could be found in Lassa and Marburg virus [78], SIV [79]
and Kaposi's sarcoma-associated herpesvirus (KSHV) [80]. Direct
interactions between tetherin and HIV virions have also been noted
[81]. However, there is still some controversy concerning the detailed
mechanisms by which Vpu can downregulate tetherin [82–84].
Varthakavi et. al. reported another cellular factor, calcium-modulating
cyclophilin ligand (CAML) , a second cellular restriction factor that Vpu
antagonizes to enhance HIV-1 release [85]. Currently, the manner in
whichVpuovercomesCAML restriction effect is not clear. Although itwas
proved that theVpu function is associatedwith virus release, the question
of whether the ion channel activity of the transmembrane domain is
required for the viral release is still debated. TASK-1 offered a very good
opportunity to link them together. However, available evidence remains
inadequate to demonstrate whether TASK-1–Vpu interaction is really
important for the regulation of HIV release.We trust that future evidence
will illuminate thedetailed relationshipbetween the functionsofVpuand
the HIV life cycle.
2.4. HCV p7
The p7 protein from HCV is the cleavage product from an E2-NS2
intermediate which consists of only 63 amino acids [86]. It has two
transmembrane domains and is mainly located on ER, mitochondrial
and plasma membranes [87,88]. Its ion channel activity was ﬁrst
reported in 2003 by using lipid bilayer system [28,29]. Little is known
about the functionofp7 in the virus life cycle. Itwas found to be essential
for HCV infection in an in vivo study [89]. After the discovery of the HCV
cell culture system, more data suggested that p7 could facilitate virus
assembly and release, functioning mainly at the late stage of virus
propagation [90]. Recently, the establishmentof a trans-complementary
system of p7 provided us a powerful tool with which to study the
function of p7 in the HCV life cycle. It also led to the hypothesis that p7
could affect virus in two aspects: its own function and the cleavage of an
E2- p7-NS2 intermediate [91]. However, the study of p7 is just at its
beginning, the links between p7 function and virus propagation remain
to be found and their mechanisms remain to be illuminated.
2.5. Picornavirus 2B
Picornaviruses are small positive strand RNA viruses which express
their mature proteins from a poly protein that will be cleaved by
protease. 2B protein is one of these mature proteins which consists of
about 99 amino acids (varies in different viruses). Until now, most
studies have been focused on 2B from polovirus and coxsackievirus B3.
2B protein is mainly localized on ER and Golgi [8,92]. It can form
dimers and tetramers, as has been proven by yeast two-hybrid [93,94]
and ﬂuorescent resonance energy transfer microscopy [95]. At ﬁrst, it
was reported that 2B, alongwith its precursor 2BC and anothermatured
protein 3A, could modify membrane permeability to hygromycin B
[4,5,96]. These data led to studies indicating that 2B can form a viroporin
and contribute to the viral life cycle.2B proteins are involved in several cellular and viral life stages. 2B in
poliovirus was found to be associated with cellular protein secretion [5]
and the disassembly of the Golgi complex, the same phenomenon that
can be induced by poliovirus infection [97]. Moreover, some in vitro
studies showed that insertion of poliovirus 2B protein into lipid bilayers
can modulate the permeability of the membrane, even allowing the
passage of small molecules [98] . In coxsackievirus B3, 2B protein was
reported to facilitate virus release by inducing a calcium efﬂux from
endoplasmic reticulum into the cell plasma [7]. The hypothesis is that 2B
protein can suppress cell apoptosis by manipulating calcium homeo-
stasis and thus can protect virus from some host anti-viral mechanisms
[99]. However, it is still unclear whether 2B protein can adjust the
calcium concentration by itself or by affecting some other host proteins.
Our recent studies on enterovirus 71 2B protein showed that 2B could
induce a chloride-selective current in Xenopus oocytes and could aid in
virus release. Its detailed mechanisms need further investigation [Xie
et al. in submission].
2.6. Coronavirus E and 3a
InCoronaviridae, itwas demonstrated that the envelope (E) proteins
of MHV, SARS-CoV, HCoV-229E and IBV exhibit viroporin activity
[35,37,38,100–103]. The E protein of SARS-CoV is 76 amino acids long,
contains one predicted TM domain and forms a pentameric ion channel
[35,36,103,104]. The SARS-CoV E protein is more selective for Na+ than
for K+ ions, status similar to that of Alphavirus 6 K proteins [11].
Although E protein is not essential for MHV replication, the E gene
deletedMHV recombinant virus showed low growth rate and low titer,
and produced small plaques [105]. Previously, E protein was demon-
strated to play a role in viral assembly and morphogenesis [106–108],
but how its ion channel activity mediates these functions is still
unknown.
Our laboratory found that another protein, 3a of SARS-CoV, could
form an ion channel and modulate viral release [39]. The ORF3 gene of
SARS-CoV encodes a 274aa protein, containing three TM domains [40]
and forms homo-tetramers [39]. When 3a is expressed in Xenopus
oocytes, the K+ channel activity was detected and could be blocked by
Ba2+. The siRNAknockdownexperiment showed that 3a protein plays a
role in viral release.Wepredicted the existenceof 3aproteinhomologue
in different human coronaviruses, and its location between coronavirus
Spike (S) gene and Envelop (E) gene on the viral genome. For
convenience, we called this gene SNE [40]. Our recent work demon-
strated that other SNE genes, such as PEDV ORF3, also encode an ion
channel protein [Wang et. al. in submission]. Since it contains three TM
domains and a relative long cytoplasmic domain, SARS-CoV3aprotein is
larger than previously reported viroporins, including coronavirus E
protein. It was well documented that the N terminus of HIV-1 Vpu
encoding the TM domain forms ion channels and modulates viral
release, while its cytoplasmic domain hasmany other functions, such as
CD4 degradation [65],. The cytoplasmic part of 3a may also have many
interesting functions, and it has been already reported that 3a protein
containsputativebinding sites for caveolin-1 [109], and their interaction
has been demonstrated by Padhan et al. [110].
3. Viral channel as drug target
One of themain reasons for the focus on virus ion channels was that
they may serve as ideal anti-viral drug targets. Amantadine was one of
the most studied and famous inhibitors for the inﬂuenza A virus M2
proton channel. Although encumbered with severe side effects,
amantadine has been used clinically as an anti-inﬂuenza drug since
1966 [111]. Then in 1985, a study indicated that several mutations,
which could lead to resistance to amantadine, were located in a
hydrophobic sequence inM2. This data suggested thatM2might be the
target for amantadine [112]. Then, in 1992 direct evidence was offered
indicating that amantadine could inhibit an early M2-dependent stage
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amantadine were regarded as a very good model in which to study the
structure of M2 and mutations induced by drug-related selection
pressure. There were two papers explaining the structure-based
mechanism of the manner in which mutations in M2 can lead to drug
resistance to amantadine [114,115].
Amiloride derivatives were reported to block HIV-1 Vpu and
coronavirus E protein ion channel activity [38,116]. The newly
discovered HCV ion channel protein p7 was likely to become the
ﬁrst anti-viral drug screen target used in practice. After the
identiﬁcation of p7 ion channel activity, several studies revealed
that this activity can be inhibited by amantadine [28], hexamethylene
amiloride (HMA) [117] and long-alkyl-chain iminosugar derivatives
[29]. Interestingly, although the amino acid sequences of p7 vary in
different genotypes of HCV, all of them have a speciﬁc reaction in
response to these drug treatments [118], indicating that p7might be a
good target for anti-HCV drug screening. Furthermore, an in vitro
liposome-based drug screen system has been established [119,120],
appears very helpful in investigation of viral ion channel activity and
may be developed into a suitablemethod for anti-viral drug screening.
4. Summary
The ion channel proteinswere found inmany different virus families,
play important roles in the life cycle of viruses, and serve as promising
anti-viral drug targets. PBCV-1 Kcv and inﬂuenza A virus M2 are highly
selective channel components, which form potassium channel and
proton channel, respectively. In contrast, other viral ion channel
proteins, such as HIV-1 Vpu and HCV p7 are permeable to both Na+
andK+ ions, anddisplay relatively low ion selectivity. As thesmallestK+
channel, Kcv contains a motif of eight amino acids, TXXTXGFG, which is
common to all the potassium channels. The channel structure and
function studied in inﬂuenza A virus M2 are well deﬁned. However,
these elements remain unclear with respect to other viral ion channel
proteins.
Although great effort has been spent in this ﬁeld, there are still
many questions remaining to be answered. Firstly, as the ion channel
activity of most viroporins was identiﬁed by using an in vitro system
such as lipid bilayer or Xenopus oocytes, their real biological function
in virus-infected cells or animals remains to be investigated. Only the
ion channel activity of Kcv and A/M2 was directly associated with a
viral life cycle stage [46,112,113]. The function of the ion channel
activity for different viroporins (such as HIV-1 Vpu, HCV p7,
coronavirus E and 3a protein) is related to promotion of virus release,
but the detailedmechanism remains to be investigated. However, Vpu
was reported to act against host factor; and 2B and 3A from
picornaviruses were also found to be inhibitory with regard to cell
trafﬁcking. None of these functions was proved to be directly related
to its ion channel activity.
Secondly, the manner in which viral ion channel proteins interact
with other host factors is also an important issue. As most of the ion
channel proteins have both a transmembrane domain and cytoplas-
mic domain, it is quite likely that the cytoplasmic domainmay interact
with some host molecules and have some interesting functions. The
study in Vpu has suggested that its function is associated with βTrCP
and the ER-associated protein degradation pathway, a notion that can
be used to explain many important functions of Vpu, such as CD4
degradation and Tetherin antagonism. Both SARS-Cov 3a protein and
inﬂuenza A virusM2 have been reported to interact with caveolin-1. It
is generally believed that such interaction with host factors could
reﬂect a newly discovered function of viral ion channel proteins.
Finally, drug screening through the use of viral ion channel proteins
has drawn more and more attention. In the past most inhibitors were
ﬁrst checked on virus and then on ion channel proteins. Now high
throughput methods have been developed to achieve the same goal by
directly testing compounds on viral channels. Given that ion channelshave very important functions in the cells and that inhibitors blocking
viral ion channels might therefore be harmful to cells, it might be better
to use these inhibitors over a short period to transiently reduce virus
titer in vivo but not to regard themas long-term treatment. On the other
hand, somechemicalmodiﬁcationsmay also reduce the toxicity of these
potential drugs. Nevertheless, viral ion channel proteins have provided
us an alternative new targetwithwhich to discover newdrugs and ﬁght
viral infection.References
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